Abstract
Background
Although the dilated phase of hypertrophic cardiomyopathy (D‐HCM) characterized by left ventricular (LV) systolic dysfunction and cavity dilatation has been reported to be a poor prognosis, this is now in contrast to the improved prognosis of dilated cardiomyopathy (DCM) in the era of advancements in heart failure management. There has been no investigation of the clinical features of D‐HCM compared with those of DCM from the point of management of systolic dysfunction.
Hypothesis
The aim of this study was to investigate the clinical features of D‐HCM in comparison with those of DCM in a single institute.
Methods
We studied 20 consecutive patients with D‐HCM (global ejection fraction < 50%) and 115 consecutive patients with DCM.
Results
At diagnosis of D‐HCM, 8 (40%) of the D‐HCM patients already experienced dyspnea (New York Heart Association [NYHA] class ≥ III). Left atrial diameter was larger and prevalence of atrial fibrillation was higher in the D‐HCM group, although LV size was larger and LV ejection fraction was lower in the DCM group. During the follow‐up period (4.0 years), 11 (55%) of the patients with D‐HCM died. The 5‐year survival rate from all‐cause mortality including cardiac transplantation was 45.6% in patients with D‐HCM vs 81.6% in patients with DCM (log‐rank P = .0001).
Conclusions
Patients with D‐HCM were more symptomatic at diagnosis, although LV dilatation and impaired fractional shortening seemed more severe in patients with DCM. The prognosis for D‐HCM patients was worse than that for patients with DCM despite similar or even more intensive treatment for heart failure. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (328.1 KB).
References
- 1. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA. 2002; 287: 1308–1320. [DOI] [PubMed] [Google Scholar]
- 2. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy‐related death: revisited in a large non‐referral‐based patient population. Circulation. 2000; 102: 858–864. [DOI] [PubMed] [Google Scholar]
- 3. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989; 320: 749–755. [DOI] [PubMed] [Google Scholar]
- 4. Biagini E, Coccolo F, Ferlito M, et al. Dilated‐hypokinesis evolution of hypertrophic cardiomyopathy. Prevalence, incidence, risk factors, and prognostic implications in pediatrics and adult patients. J Am Coll Cardiol. 2005; 46: 1543–1550. [DOI] [PubMed] [Google Scholar]
- 5. Thaman R, Gimeno JR, Mutphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005; 91: 920–925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end‐stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114: 216–225. [DOI] [PubMed] [Google Scholar]
- 7. Kubo T, Kitaoka H, Okawa M, et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin‐binding protein C gene among Japanese. J Am Coll Cardiol. 2005; 46: 1737–1743. [DOI] [PubMed] [Google Scholar]
- 8. Matsumura Y, Takata J, Kitaoka H, et al. Long‐term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years. Circ J. 2006; 70: 376–383. [DOI] [PubMed] [Google Scholar]
- 9. Kitaoka H, Kubo T, Okawa M, Hitomi N, Furuno T, Doi YL. Left ventricular remodeling of hypertrophic cardiomyopathy: longitudinal observation in a rural community. Circ J. 2006; 70: 1543–1549. [DOI] [PubMed] [Google Scholar]
- 10. Walter TA, Hister WL, Capehart JE, Roberts WC. Comparison of clinical and morphologic cardiac findings in patients having cardiac transplantation for ischemic cardiomyopathy, idiopathic dilated cardiomyopathy, and dilated hypertrophic cardiomyopathy. Am J Cardiol. 1998; 81: 884–894. [DOI] [PubMed] [Google Scholar]
- 11. Lim D, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001; 103: 789–791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, survival in rat heart failure. Circulation. 2001; 103: 148–154. [DOI] [PubMed] [Google Scholar]
- 13. Rogers DPS, Marazia S, Chow AW, et al. Effect of biventricular pacing on symptoms and cardiac remodeling in patients with end‐stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2008; 10: 507–513. [DOI] [PubMed] [Google Scholar]
- 14. Maron BJ, Shen W, Link MS, et al. Efficacy of implantable cardioverter‐defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342: 365–373. [DOI] [PubMed] [Google Scholar]
- 15. Moon JC, Reed E, Sheppard MN, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004; 43: 2260–2264. [DOI] [PubMed] [Google Scholar]